Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms

被引:109
作者
McLoughlin, RM
Hurst, SM
Nowell, MA
Harris, DA
Horiuchi, S
Morgan, LW
Wilkinson, TS
Yamamoto, N
Topley, N
Jones, SA
机构
[1] Cardiff Univ, Cardiff Sch Biosci, Mol Cell Biol Res Grp, Cardiff CF10 3US, S Glam, Wales
[2] Tokyo Med & Dent Univ, Dept Microbiol, Tokyo, Japan
[3] Cardiff Univ, Inst Nephrol, Cardiff CF4 4XN, S Glam, Wales
关键词
D O I
10.4049/jimmunol.172.9.5676
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-6 signaling via its soluble receptor (sIL-6R) differentially regulates inflammatory chemokine expression and leukocyte apoptosis to coordinate transition from neutrophil to mononuclear cell infiltration. sIL-6R activities may, however, be influenced in vivo by the occurrence of two sIL-6R isoforms that are released as a consequence of differential mRNA splicing (DS) or proteolytic cleavage (PC) of the cognate IL-6R (termed DS- and PC-sIL-6R). Using human peritoneal mesothelial cells and a murine model of peritoneal inflammation, studies described in this work have compared the ability of both isoforms to regulate neutrophil recruitment. In this respect, DS- and PC-sIL-6R were comparable in their activities; however, these studies emphasized that IL-6 trans signaling differentially controls neutrophil-activating CXC chemokine expression. In vitro, stimulation of mesothelial cells with IL-6 in combination with either DS-sIL-6R or PC-sIL-6R showed no induction of CXC chemokine ligand (CXCL)1 (GROalpha) and CXCL8 (IL-8), whereas both isoforms enhanced CXCL5 (ENA-78) and CXCL6 (granulocyte chemotactic protein-2) expression. Moreover, when complexed with IL-6, both isoforms specifically inhibited the IL-1beta-induced secretion of CXCL8. These findings were paralleled in vivo, in which induction of peritoneal inflammation in IL-6-deficient (IL-6(-/-)) mice resulted in enhanced keratinocyte-derived chemokine and macrophage-inflammatory protein-2 (the murine equivalent of CXCL1 and CXCL8) levels, but reduced LPS-induced CXC chemokine (the murine equivalent of CXCL5) expression. Reconstitution of IL-6 signaling in IL-6(-/-) mice with IL-6 and its soluble receptor isoforms corrected this chemokine imbalance and suppressed overall neutrophil infiltration. These data confirm that sIL-6R-mediated signaling primarily limits neutrophil influx; however, induction of CXCL5 and CXCL6 may regulate other neutrophil responses.
引用
收藏
页码:5676 / 5683
页数:8
相关论文
共 51 条
[1]   The CXC chemokines growth-regulated oncogene (GRO) alpha, GRO beta, GRO gamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor [J].
Ahuja, SK ;
Murphy, PM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (34) :20545-20550
[2]   Chemokines and leukocyte traffic [J].
Baggiolini, M .
NATURE, 1998, 392 (6676) :565-568
[3]   Chemokine-cytokine cross-talk -: The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-κB pathway [J].
Chandrasekar, B ;
Melby, PC ;
Sarau, HM ;
Raveendran, M ;
Perla, RP ;
Marelli-Berg, FM ;
Dulin, NO ;
Singh, IS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (07) :4675-4686
[4]  
CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587
[5]  
Cichy J, 1997, J IMMUNOL, V159, P5648
[6]   Blood monocytes consist of two principal subsets with distinct migratory properties [J].
Geissmann, F ;
Jung, S ;
Littman, DR .
IMMUNITY, 2003, 19 (01) :71-82
[7]   Interleukin-8 (IL-8), melanoma growth-stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil NADPH oxidase through the type A or type B IL-8 receptor [J].
Green, SP ;
Chuntharapai, A ;
Curnutte, JT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (41) :25400-25405
[8]  
HONDA M, 1992, J IMMUNOL, V148, P2175
[9]   SOLUBLE INTERLEUKIN-6 RECEPTORS RELEASED FROM T-CELL OR GRANULOCYTE/MACROPHAGE CELL-LINES AND HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS ARE GENERATED THROUGH AN ALTERNATIVE SPLICING MECHANISM [J].
HORIUCHI, S ;
KOYANAGI, Y ;
ZHOU, YW ;
MIYAMOTO, H ;
TANAKA, Y ;
WAKI, M ;
MATSUMOTO, A ;
YAMAMOTO, M ;
YAMAMOTO, N .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (08) :1945-1948
[10]  
Horiuchi S, 1998, IMMUNOLOGY, V95, P360, DOI 10.1046/j.1365-2567.1998.00622.x